{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "04ad8d34",
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "import yfinance as yf\n",
    "from datetime import datetime\n",
    "from datetime import timedelta\n",
    "import pandas as pd\n",
    "import json\n",
    "\n",
    "def changes_from_press(stock_data, press_date, period):\n",
    "    next_day = timedelta(days=1)\n",
    "    time_after_release = timedelta(days=period)\n",
    "    \n",
    "\n",
    "    next_trading_day = press_date\n",
    "    \n",
    "    # try to obtain share price at open on press release date\n",
    "    day_1_price = stock_data[stock_data['Date'] == press_date]['Open'].values\n",
    "\n",
    "\n",
    "    # increase the date till the first available open price is found\n",
    "    num_days = 1\n",
    "    while not day_1_price:\n",
    "        if num_days > 30:\n",
    "            return None\n",
    "        \n",
    "        next_trading_day = next_trading_day + next_day\n",
    "\n",
    "        day_1_price = stock_data[stock_data['Date'] == (next_trading_day)]['Open'].values\n",
    "        num_days = num_days + 1\n",
    "\n",
    "    # get next day if available\n",
    "    next_trading_day = next_trading_day + time_after_release\n",
    "    day_2_price = stock_data[stock_data['Date'] == (next_trading_day)]['Close'].values\n",
    "\n",
    "    # increase the date till the second available close price is found\n",
    "    num_days = 1\n",
    "    while not day_2_price:\n",
    "        if num_days > 30: \n",
    "            return None\n",
    "        \n",
    "        next_trading_day = next_trading_day + next_day\n",
    "\n",
    "        day_2_price = stock_data[stock_data['Date'] == (next_trading_day + next_day)]['Close'].values\n",
    "        num_days = num_days + 1\n",
    "    \n",
    "    # calcualte percent difference between share prices\n",
    "    pct_change = ((day_2_price - day_1_price) / day_2_price)*100\n",
    "    pct_change = pct_change[0]\n",
    "    return pct_change\n",
    "\n",
    "def get_df(ticker):\n",
    "    \n",
    "    stock_data = yf.Ticker(ticker)\n",
    "\n",
    "    # get historical market data\n",
    "    stock_hist = stock_data.history(period=\"max\")\n",
    "\n",
    "    stock_hist.reset_index(inplace=True)\n",
    "\n",
    "    stock_hist['Date'] = pd.to_datetime(stock_hist['Date']).dt.date\n",
    "\n",
    "    stock_hist['Pct_Close'] = stock_hist['Close'].pct_change()*100\n",
    "\n",
    "    return stock_hist"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2a0da762",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\Aidan\\AppData\\Local\\Temp\\ipykernel_18272\\3129314641.py:37: DeprecationWarning: The truth value of an empty array is ambiguous. Returning False, but in future this will result in an error. Use `array.size > 0` to check that an array is not empty.\n",
      "  while not day_2_price:\n",
      "C:\\Users\\Aidan\\AppData\\Local\\Temp\\ipykernel_18272\\3129314641.py:22: DeprecationWarning: The truth value of an empty array is ambiguous. Returning False, but in future this will result in an error. Use `array.size > 0` to check that an array is not empty.\n",
      "  while not day_1_price:\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[datetime.date(2023, 4, 27), 'Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum', None], [datetime.date(2023, 4, 27), \"Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2\", None], [datetime.date(2023, 4, 24), 'Lilly to Divest BAQSIMI to Amphastar', -0.10393771445033984], [datetime.date(2023, 4, 17), 'Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities', -1.3760093772808675], [datetime.date(2023, 4, 13), 'U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab', 0.563076296874874], [datetime.date(2023, 4, 13), 'Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement', 0.563076296874874], [datetime.date(2023, 3, 14), 'Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting', 1.645070388093893], [datetime.date(2023, 3, 8), \"Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease\", 2.004104775507267], [datetime.date(2023, 3, 8), 'US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes', 2.004104775507267], [datetime.date(2023, 3, 6), 'Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study', -2.0313548142183637], [datetime.date(2023, 3, 3), 'U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer', 0.8120129192615044], [datetime.date(2023, 3, 1), 'Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month', 1.602916358875496], [datetime.date(2023, 2, 21), \"Lilly to Participate in Cowen's 43rd Annual Health Care Conference\", 0.5834665527091526], [datetime.date(2023, 2, 13), 'Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh', 0.6350924742413218], [datetime.date(2023, 2, 7), 'Lilly to Participate in SVB Securities Global Biopharma Conference', 1.3735279522019026], [datetime.date(2023, 2, 3), 'Lilly to Participate in Guggenheim Oncology Conference', 1.3948912300949747], [datetime.date(2023, 2, 2), 'Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook', 1.4981634905367671], [datetime.date(2023, 1, 27), 'U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor', -1.6475735096717476], [datetime.date(2023, 1, 26), \"Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity\", -2.601572434644426], [datetime.date(2023, 1, 24), 'Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park', 1.066539689439987], [datetime.date(2023, 1, 20), 'US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease', -1.3997270099784656], [datetime.date(2023, 1, 19), 'U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab', -1.8204412062687716], [datetime.date(2023, 1, 19), 'Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement', -1.8204412062687716], [datetime.date(2023, 1, 4), 'Lilly to Participate in the J.P. Morgan Healthcare Conference', -1.5936676996874373], [datetime.date(2022, 12, 22), 'Lilly and ProQR to Expand RNA Editing Collaboration', 0.15765367903162142], [datetime.date(2022, 12, 14), 'Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa', 0.2777633000855462], [datetime.date(2022, 12, 13), 'Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines', 0.5144454379482337], [datetime.date(2022, 12, 12), 'Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting', -1.1905372928391267], [datetime.date(2022, 12, 12), 'Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend', -1.1905372928391267], [datetime.date(2022, 12, 7), 'Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes', 0.6643536801099604], [datetime.date(2022, 12, 6), 'Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology', 1.3361333183020125], [datetime.date(2022, 12, 1), 'Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases', -0.008003692167022822], [datetime.date(2022, 11, 30), \"Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease\", 1.4203471925857263], [datetime.date(2022, 11, 30), 'Lilly and Akouos Announce Expiration of Akouos Tender Offer', 1.4203471925857263], [datetime.date(2022, 11, 29), 'Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement', 1.7408659271112261], [datetime.date(2022, 11, 21), 'Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium', 0.1357710242288256], [datetime.date(2022, 11, 16), 'Lilly to Participate in Evercore ISI HealthCONx Conference', 2.9852741809820893], [datetime.date(2022, 11, 7), 'Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform', 2.3618578930027803], [datetime.date(2022, 11, 4), 'Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease', -0.03560718962506887], [datetime.date(2022, 11, 3), 'Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting', 0.9372989552201737], [datetime.date(2022, 11, 1), 'Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress', 2.5721200946501046], [datetime.date(2022, 10, 27), 'Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration', 0.25284578662115315], [datetime.date(2022, 10, 19), 'Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement', -1.878010363156549], [datetime.date(2022, 10, 18), 'Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss', -1.4728779885558514], [datetime.date(2022, 10, 17), 'Lilly Declares Fourth-Quarter 2022 Dividend', 0.6685950724671748], [datetime.date(2022, 10, 6), 'Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities', -0.39184606778708125], [datetime.date(2022, 9, 21), \"FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type\", 3.1749600452482944], [datetime.date(2022, 9, 8), \"Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials\", 1.8098870160085119], [datetime.date(2022, 9, 7), 'Lilly Announces Details of Presentations at ESMO Congress 2022', 2.133120453138954], [datetime.date(2022, 8, 31), 'Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference', 0.6437450538576569], [datetime.date(2022, 8, 25), \"Lilly to Participate in Citi's 17th Annual BioPharma Conference\", -1.5971703182779382], [datetime.date(2022, 8, 11), 'Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly', 2.6063238555414276], [datetime.date(2022, 8, 8), \"Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience\", 0.782138203913299], [datetime.date(2022, 8, 4), 'Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results', -2.947047822036282], [datetime.date(2022, 8, 4), 'Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements', -2.947047822036282], [datetime.date(2022, 7, 21), 'Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement', 2.2205250188165917], [datetime.date(2022, 6, 29), 'Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options', 1.8721309669185282], [datetime.date(2022, 6, 27), 'Lilly Declares Third-Quarter 2022 Dividend', -2.081121053367924], [datetime.date(2022, 6, 13), \"FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata\", 0.12379312058463342], [datetime.date(2022, 6, 7), \"Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials\", 3.030404512024831], [datetime.date(2022, 6, 6), \"New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®\", -0.9708420916849521], [datetime.date(2022, 6, 5), 'Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study', -0.9708420916849521], [datetime.date(2022, 6, 4), \"Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo\", -0.9708420916849521], [datetime.date(2022, 6, 4), \"Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight\", -0.9708420916849521], [datetime.date(2022, 6, 3), 'Lilly to Participate in Goldman Sachs Global Healthcare Conference', 0.39556669541775735], [datetime.date(2022, 5, 26), 'Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting', 5.641772878398372], [datetime.date(2022, 5, 25), 'Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana', 2.060868798841787], [datetime.date(2022, 5, 24), \"Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study\", 1.0748860251922026], [datetime.date(2022, 5, 23), 'Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA', 1.751852875300683], [datetime.date(2022, 5, 20), \"CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)\", 3.9226629845775887], [datetime.date(2022, 5, 16), 'Lilly to Participate in UBS Global Healthcare Conference 2022', 3.082286411434026], [datetime.date(2022, 5, 13), \"FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes\", 2.2546649474292204], [datetime.date(2022, 5, 11), \"FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19\", 2.7861466985285457], [datetime.date(2022, 5, 6), 'Mary Lynne Hedley Elected to Lilly Board of Directors', -0.32499770991781674], [datetime.date(2022, 5, 3), 'Lilly to Participate in Bank of America Securities 2022 Healthcare Conference', 2.126150002436917], [datetime.date(2022, 5, 2), 'Lilly Declares Second-Quarter 2022 Dividend', -1.0969483152413997], [datetime.date(2022, 4, 28), \"Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022\", -1.3213391911635186], [datetime.date(2022, 4, 28), \"Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1\", -1.3213391911635186], [datetime.date(2022, 4, 20), 'Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care', -2.5586174456830766], [datetime.date(2022, 4, 19), 'Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement', -1.8742310890033445], [datetime.date(2022, 4, 11), \"Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis\", -1.6262059639210544], [datetime.date(2022, 4, 1), 'Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress', 1.8083989238519333], [datetime.date(2022, 3, 26), \"Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies\", -1.0194406427710274], [datetime.date(2022, 3, 26), \"Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies\", -1.0194406427710274], [datetime.date(2022, 3, 24), 'Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer', 0.9445790576834895], [datetime.date(2022, 3, 16), 'Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease', 2.682927885574432], [datetime.date(2022, 3, 8), 'Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)', 1.088339801087881], [datetime.date(2022, 3, 3), 'Lilly to Participate in Barclays Global Healthcare Conference', 3.058547747753866], [datetime.date(2022, 3, 1), 'Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial', 2.600627357040398], [datetime.date(2022, 2, 28), 'Lilly to Participate in Cowen Health Care Conference', 1.3466912095175478], [datetime.date(2022, 2, 24), 'US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction', 6.246763612611943], [datetime.date(2022, 2, 22), 'Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site', -0.3776694141710003], [datetime.date(2022, 2, 18), \"Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study\", 0.46417482851097613], [datetime.date(2022, 2, 16), 'Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence', -0.66813030557565], [datetime.date(2022, 2, 11), \"Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19\", -1.5107225438257998], [datetime.date(2022, 2, 10), 'Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options', -1.7646529157847102], [datetime.date(2022, 2, 10), 'Cynthia Cardona Elected as President of the Lilly Foundation', -1.7646529157847102], [datetime.date(2022, 2, 3), 'Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients', -2.1587401543947347], [datetime.date(2022, 2, 2), 'UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents', -0.22058035412364224], [datetime.date(2022, 2, 1), 'Lilly to Participate in Guggenheim Oncology Conference', 1.506995873785084]]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[datetime.date(2023, 4, 27), 'Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum', None], [datetime.date(2023, 4, 27), \"Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2\", None], [datetime.date(2023, 4, 24), 'Lilly to Divest BAQSIMI to Amphastar', -0.10393771445033984], [datetime.date(2023, 4, 17), 'Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities', -1.3760093772808675], [datetime.date(2023, 4, 13), 'U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab', 0.563076296874874], [datetime.date(2023, 4, 13), 'Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement', 0.563076296874874], [datetime.date(2023, 3, 14), 'Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting', 1.645070388093893], [datetime.date(2023, 3, 8), \"Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease\", 2.004104775507267], [datetime.date(2023, 3, 8), 'US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes', 2.004104775507267], [datetime.date(2023, 3, 6), 'Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study', -2.0313548142183637], [datetime.date(2023, 3, 3), 'U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer', 0.8120129192615044], [datetime.date(2023, 3, 1), 'Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month', 1.602916358875496], [datetime.date(2023, 2, 21), \"Lilly to Participate in Cowen's 43rd Annual Health Care Conference\", 0.5834665527091526], [datetime.date(2023, 2, 13), 'Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh', 0.6350924742413218], [datetime.date(2023, 2, 7), 'Lilly to Participate in SVB Securities Global Biopharma Conference', 1.3735279522019026], [datetime.date(2023, 2, 3), 'Lilly to Participate in Guggenheim Oncology Conference', 1.3948912300949747], [datetime.date(2023, 2, 2), 'Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook', 1.4981634905367671], [datetime.date(2023, 1, 27), 'U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor', -1.6475735096717476], [datetime.date(2023, 1, 26), \"Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity\", -2.601572434644426], [datetime.date(2023, 1, 24), 'Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park', 1.066539689439987], [datetime.date(2023, 1, 20), 'US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease', -1.3997270099784656], [datetime.date(2023, 1, 19), 'U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab', -1.8204412062687716], [datetime.date(2023, 1, 19), 'Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement', -1.8204412062687716], [datetime.date(2023, 1, 4), 'Lilly to Participate in the J.P. Morgan Healthcare Conference', -1.5936676996874373], [datetime.date(2022, 12, 22), 'Lilly and ProQR to Expand RNA Editing Collaboration', 0.15765367903162142], [datetime.date(2022, 12, 14), 'Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa', 0.2777633000855462], [datetime.date(2022, 12, 13), 'Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines', 0.5144454379482337], [datetime.date(2022, 12, 12), 'Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting', -1.1905372928391267], [datetime.date(2022, 12, 12), 'Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend', -1.1905372928391267], [datetime.date(2022, 12, 7), 'Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes', 0.6643536801099604], [datetime.date(2022, 12, 6), 'Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology', 1.3361333183020125], [datetime.date(2022, 12, 1), 'Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases', -0.008003692167022822], [datetime.date(2022, 11, 30), \"Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease\", 1.4203471925857263], [datetime.date(2022, 11, 30), 'Lilly and Akouos Announce Expiration of Akouos Tender Offer', 1.4203471925857263], [datetime.date(2022, 11, 29), 'Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement', 1.7408659271112261], [datetime.date(2022, 11, 21), 'Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium', 0.1357710242288256], [datetime.date(2022, 11, 16), 'Lilly to Participate in Evercore ISI HealthCONx Conference', 2.9852741809820893], [datetime.date(2022, 11, 7), 'Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform', 2.3618578930027803], [datetime.date(2022, 11, 4), 'Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease', -0.03560718962506887], [datetime.date(2022, 11, 3), 'Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting', 0.9372989552201737], [datetime.date(2022, 11, 1), 'Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress', 2.5721200946501046], [datetime.date(2022, 10, 27), 'Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration', 0.25284578662115315], [datetime.date(2022, 10, 19), 'Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement', -1.878010363156549], [datetime.date(2022, 10, 18), 'Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss', -1.4728779885558514], [datetime.date(2022, 10, 17), 'Lilly Declares Fourth-Quarter 2022 Dividend', 0.6685950724671748], [datetime.date(2022, 10, 6), 'Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities', -0.39184606778708125], [datetime.date(2022, 9, 21), \"FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type\", 3.1749600452482944], [datetime.date(2022, 9, 8), \"Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials\", 1.8098870160085119], [datetime.date(2022, 9, 7), 'Lilly Announces Details of Presentations at ESMO Congress 2022', 2.133120453138954], [datetime.date(2022, 8, 31), 'Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference', 0.6437450538576569], [datetime.date(2022, 8, 25), \"Lilly to Participate in Citi's 17th Annual BioPharma Conference\", -1.5971703182779382], [datetime.date(2022, 8, 11), 'Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly', 2.6063238555414276], [datetime.date(2022, 8, 8), \"Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience\", 0.782138203913299], [datetime.date(2022, 8, 4), 'Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results', -2.947047822036282], [datetime.date(2022, 8, 4), 'Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements', -2.947047822036282], [datetime.date(2022, 7, 21), 'Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement', 2.2205250188165917], [datetime.date(2022, 6, 29), 'Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options', 1.8721309669185282], [datetime.date(2022, 6, 27), 'Lilly Declares Third-Quarter 2022 Dividend', -2.081121053367924], [datetime.date(2022, 6, 13), \"FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata\", 0.12379312058463342], [datetime.date(2022, 6, 7), \"Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials\", 3.030404512024831], [datetime.date(2022, 6, 6), \"New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®\", -0.9708420916849521], [datetime.date(2022, 6, 5), 'Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study', -0.9708420916849521], [datetime.date(2022, 6, 4), \"Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo\", -0.9708420916849521], [datetime.date(2022, 6, 4), \"Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight\", -0.9708420916849521], [datetime.date(2022, 6, 3), 'Lilly to Participate in Goldman Sachs Global Healthcare Conference', 0.39556669541775735], [datetime.date(2022, 5, 26), 'Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting', 5.641772878398372], [datetime.date(2022, 5, 25), 'Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana', 2.060868798841787], [datetime.date(2022, 5, 24), \"Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study\", 1.0748860251922026], [datetime.date(2022, 5, 23), 'Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA', 1.751852875300683], [datetime.date(2022, 5, 20), \"CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)\", 3.9226629845775887], [datetime.date(2022, 5, 16), 'Lilly to Participate in UBS Global Healthcare Conference 2022', 3.082286411434026], [datetime.date(2022, 5, 13), \"FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes\", 2.2546649474292204], [datetime.date(2022, 5, 11), \"FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19\", 2.7861466985285457], [datetime.date(2022, 5, 6), 'Mary Lynne Hedley Elected to Lilly Board of Directors', -0.32499770991781674], [datetime.date(2022, 5, 3), 'Lilly to Participate in Bank of America Securities 2022 Healthcare Conference', 2.126150002436917], [datetime.date(2022, 5, 2), 'Lilly Declares Second-Quarter 2022 Dividend', -1.0969483152413997], [datetime.date(2022, 4, 28), \"Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022\", -1.3213391911635186], [datetime.date(2022, 4, 28), \"Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1\", -1.3213391911635186], [datetime.date(2022, 4, 20), 'Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care', -2.5586174456830766], [datetime.date(2022, 4, 19), 'Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement', -1.8742310890033445], [datetime.date(2022, 4, 11), \"Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis\", -1.6262059639210544], [datetime.date(2022, 4, 1), 'Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress', 1.8083989238519333], [datetime.date(2022, 3, 26), \"Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies\", -1.0194406427710274], [datetime.date(2022, 3, 26), \"Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies\", -1.0194406427710274], [datetime.date(2022, 3, 24), 'Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer', 0.9445790576834895], [datetime.date(2022, 3, 16), 'Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease', 2.682927885574432], [datetime.date(2022, 3, 8), 'Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)', 1.088339801087881], [datetime.date(2022, 3, 3), 'Lilly to Participate in Barclays Global Healthcare Conference', 3.058547747753866], [datetime.date(2022, 3, 1), 'Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial', 2.600627357040398], [datetime.date(2022, 2, 28), 'Lilly to Participate in Cowen Health Care Conference', 1.3466912095175478], [datetime.date(2022, 2, 24), 'US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction', 6.246763612611943], [datetime.date(2022, 2, 22), 'Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site', -0.3776694141710003], [datetime.date(2022, 2, 18), \"Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study\", 0.46417482851097613], [datetime.date(2022, 2, 16), 'Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence', -0.66813030557565], [datetime.date(2022, 2, 11), \"Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19\", -1.5107225438257998], [datetime.date(2022, 2, 10), 'Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options', -1.7646529157847102], [datetime.date(2022, 2, 10), 'Cynthia Cardona Elected as President of the Lilly Foundation', -1.7646529157847102], [datetime.date(2022, 2, 3), 'Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients', -2.1587401543947347], [datetime.date(2022, 2, 2), 'UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents', -0.22058035412364224], [datetime.date(2022, 2, 1), 'Lilly to Participate in Guggenheim Oncology Conference', 1.506995873785084], [datetime.date(2022, 1, 28), 'Lilly announces $1 billion investment in new manufacturing facility in North Carolina', 3.219373079947785], [datetime.date(2022, 1, 28), 'Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis', 3.219373079947785], [datetime.date(2022, 1, 20), 'Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement', -1.0367857554481936], [datetime.date(2022, 1, 6), 'Lilly to Participate in the J.P. Morgan Healthcare Conference', -0.23120617139011923], [datetime.date(2022, 1, 6), 'Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications', -0.23120617139011923], [datetime.date(2021, 12, 21), \"Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study\", 0.9380702946135364], [datetime.date(2021, 12, 15), 'Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting', 6.0815678414386305], [datetime.date(2021, 12, 14), 'Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022', 10.004346741141648], [datetime.date(2021, 12, 13), 'Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend', 1.5518607821196164], [datetime.date(2021, 12, 13), \"Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform\", 1.5518607821196164], [datetime.date(2021, 12, 12), 'Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting', 1.5518607821196164], [datetime.date(2021, 12, 10), 'Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders', 2.9493456516334633], [datetime.date(2021, 12, 9), 'New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients', -0.14337406855395698], [datetime.date(2021, 12, 3), \"Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12\", -2.354559145359978], [datetime.date(2021, 12, 1), 'Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting', -0.6293241922072789], [datetime.date(2021, 11, 18), 'Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients', -0.4986647972662094], [datetime.date(2021, 11, 17), 'Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference', 1.7296203661647365], [datetime.date(2021, 11, 11), 'US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction', -0.7013521513074406], [datetime.date(2021, 11, 11), 'Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care', -0.7013521513074406], [datetime.date(2021, 11, 9), 'Lilly to Participate in Wolfe Research Virtual Healthcare Conference', 1.5567646475447663], [datetime.date(2021, 11, 9), 'OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis', 1.5567646475447663], [datetime.date(2021, 11, 5), 'Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status', -3.2472243999742836], [datetime.date(2021, 11, 4), 'Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting', -0.18112592746395867], [datetime.date(2021, 11, 2), 'Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19', 5.637348000416161], [datetime.date(2021, 11, 1), \"Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference\", 0.6774419629776092], [datetime.date(2021, 10, 28), 'Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology', 1.8056052073166247], [datetime.date(2021, 10, 26), 'Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential', 2.2664593459062234], [datetime.date(2021, 10, 19), 'Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk', 1.912031654073653], [datetime.date(2021, 10, 18), 'Lilly Declares Fourth-Quarter 2021 Dividend', 1.7993439823016038], [datetime.date(2021, 10, 14), 'Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology', 0.36574043734877626], [datetime.date(2021, 10, 13), 'FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer', 1.1069321865402235], [datetime.date(2021, 10, 12), 'Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement', 0.7359089399600715], [datetime.date(2021, 10, 7), 'Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics', 2.0603574938990445], [datetime.date(2021, 10, 4), 'Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals', 1.355379492630161], [datetime.date(2021, 10, 1), 'At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study', -2.7351490838861734], [datetime.date(2021, 9, 30), 'OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata', -1.3894346458519264], [datetime.date(2021, 9, 30), \"Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study\", -1.3894346458519264], [datetime.date(2021, 9, 30), \"Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study\", -1.3894346458519264], [datetime.date(2021, 9, 29), 'Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women', 2.4410264011323326], [datetime.date(2021, 9, 28), \"FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy\", 1.723390798325766], [datetime.date(2021, 9, 28), 'Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options', 1.723390798325766], [datetime.date(2021, 9, 27), 'New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary', -3.7770759406685914], [datetime.date(2021, 9, 24), 'Eli Lilly and Company\\u202fIssues Voluntary\\u202fNationwide Recall of\\u202fOne Lot of GLUCAGON® Emergency Kit Due\\u202fto Loss of Potency', -2.813599803358029], [datetime.date(2021, 9, 21), 'Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities', -1.6469554230164933], [datetime.date(2021, 9, 21), 'Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19', -1.6469554230164933], [datetime.date(2021, 9, 21), 'Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059', -1.6469554230164933], [datetime.date(2021, 9, 16), \"Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19\", -1.729692120557489], [datetime.date(2021, 9, 15), 'Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19', -1.099372905045263], [datetime.date(2021, 9, 13), 'Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference', -2.981682457560067], [datetime.date(2021, 9, 13), 'Lilly to Present New Data from Oncology Portfolio at ESMO Congress', -2.981682457560067], [datetime.date(2021, 9, 9), 'Lilly Prices First Sustainability Bond to Advance Global ESG Strategy', -5.75781467833885], [datetime.date(2021, 9, 9), 'FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction', -5.75781467833885], [datetime.date(2021, 9, 7), 'Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to \"Type 1 Diabetes Camps Initiative\"', -1.6324043487380548], [datetime.date(2021, 9, 7), 'Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities', -1.6324043487380548], [datetime.date(2021, 9, 3), 'Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference', -2.366551093120754], [datetime.date(2021, 8, 31), \"Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference\", -2.113447081259668], [datetime.date(2021, 8, 27), 'Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction', -0.08005011139647274], [datetime.date(2021, 8, 25), 'Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders', -0.5587033137737072], [datetime.date(2021, 8, 25), 'Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors', -0.5587033137737072], [datetime.date(2021, 8, 18), 'US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction', -0.5954356702913074], [datetime.date(2021, 8, 17), 'Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units', -0.9831604122598897], [datetime.date(2021, 8, 16), 'FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps', 2.8711821939552475], [datetime.date(2021, 8, 16), \"Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials\", 2.8711821939552475], [datetime.date(2021, 8, 3), 'Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance', 6.751260488686206], [datetime.date(2021, 8, 3), \"Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation\", 6.751260488686206], [datetime.date(2021, 7, 29), 'Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline', -1.64270149837966], [datetime.date(2021, 7, 29), \"FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen\", -1.64270149837966], [datetime.date(2021, 7, 29), 'Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses', -1.64270149837966], [datetime.date(2021, 7, 22), 'Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement', 2.8138425413153314], [datetime.date(2021, 7, 16), 'Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis', 0.700438682551326], [datetime.date(2021, 7, 15), \"Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab\", -1.0969686845301976], [datetime.date(2021, 7, 14), 'Lilly Announces Acquisition of Protomer Technologies', -1.866324498749989], [datetime.date(2021, 7, 9), 'Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study', -0.4915090146513157], [datetime.date(2021, 7, 6), 'Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction', 0.9286819188931776], [datetime.date(2021, 6, 29), 'Lilly Declares Third-Quarter 2021 Dividend', 0.5533246462590827], [datetime.date(2021, 6, 26), \"Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes\", 0.1613061791243181], [datetime.date(2021, 6, 25), \"Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes\", -2.1470475153989685], [datetime.date(2021, 6, 24), 'Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin', -2.0415135576723724], [datetime.date(2021, 6, 24), \"Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease\", -2.0415135576723724], [datetime.date(2021, 6, 17), 'Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine', -0.7870146812041756], [datetime.date(2021, 6, 15), 'Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine', -2.4189186065559225], [datetime.date(2021, 6, 14), 'Lilly to Participate in Guggenheim Biopharma Strategy Series', -0.3176495061632742], [datetime.date(2021, 6, 11), 'Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA', -0.4113194013479604], [datetime.date(2021, 6, 4), 'Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting', 8.86662745021121], [datetime.date(2021, 6, 3), 'Lilly to Participate in Goldman Sachs Healthcare Conference', 1.4998428843014826], [datetime.date(2021, 6, 3), \"Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021\", 1.4998428843014826], [datetime.date(2021, 6, 1), 'OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses', -0.5975984683042826], [datetime.date(2021, 6, 1), 'Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study', -0.5975984683042826], [datetime.date(2021, 5, 22), \"Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial\", -0.8934713180470056], [datetime.date(2021, 5, 20), \"Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial\", 1.3608218002768524], [datetime.date(2021, 5, 19), 'Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting', 2.966959784987537], [datetime.date(2021, 5, 18), 'U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer', 0.7684295422907699], [datetime.date(2021, 5, 13), 'Lilly to Participate in UBS Global Healthcare Virtual Conference', 2.018252692983907], [datetime.date(2021, 5, 11), 'Lilly and MiNA Therapeutics Announce saRNA Research Collaboration', -0.09834628654598798], [datetime.date(2021, 5, 6), 'Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes', 1.9803426507996016], [datetime.date(2021, 5, 5), 'Lilly to Participate in Bank of America Securities 2021 Health Care Conference', 2.702560391803232], [datetime.date(2021, 5, 4), 'Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries', 2.73844585352178], [datetime.date(2021, 5, 4), 'Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe', 2.73844585352178], [datetime.date(2021, 5, 4), \"Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements\", 2.73844585352178], [datetime.date(2021, 5, 3), 'Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization', 2.768328897627359]]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[datetime.date(2023, 4, 27), 'Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum', None], [datetime.date(2023, 4, 27), \"Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2\", None], [datetime.date(2023, 4, 24), 'Lilly to Divest BAQSIMI to Amphastar', -0.10393771445033984], [datetime.date(2023, 4, 17), 'Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities', -1.3760093772808675], [datetime.date(2023, 4, 13), 'U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab', 0.563076296874874], [datetime.date(2023, 4, 13), 'Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement', 0.563076296874874], [datetime.date(2023, 3, 14), 'Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting', 1.645070388093893], [datetime.date(2023, 3, 8), \"Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease\", 2.004104775507267], [datetime.date(2023, 3, 8), 'US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes', 2.004104775507267], [datetime.date(2023, 3, 6), 'Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study', -2.0313548142183637], [datetime.date(2023, 3, 3), 'U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer', 0.8120129192615044], [datetime.date(2023, 3, 1), 'Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month', 1.602916358875496], [datetime.date(2023, 2, 21), \"Lilly to Participate in Cowen's 43rd Annual Health Care Conference\", 0.5834665527091526], [datetime.date(2023, 2, 13), 'Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh', 0.6350924742413218], [datetime.date(2023, 2, 7), 'Lilly to Participate in SVB Securities Global Biopharma Conference', 1.3735279522019026], [datetime.date(2023, 2, 3), 'Lilly to Participate in Guggenheim Oncology Conference', 1.3948912300949747], [datetime.date(2023, 2, 2), 'Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook', 1.4981634905367671], [datetime.date(2023, 1, 27), 'U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor', -1.6475735096717476], [datetime.date(2023, 1, 26), \"Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity\", -2.601572434644426], [datetime.date(2023, 1, 24), 'Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park', 1.066539689439987], [datetime.date(2023, 1, 20), 'US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease', -1.3997270099784656], [datetime.date(2023, 1, 19), 'U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab', -1.8204412062687716], [datetime.date(2023, 1, 19), 'Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement', -1.8204412062687716], [datetime.date(2023, 1, 4), 'Lilly to Participate in the J.P. Morgan Healthcare Conference', -1.5936676996874373], [datetime.date(2022, 12, 22), 'Lilly and ProQR to Expand RNA Editing Collaboration', 0.15765367903162142], [datetime.date(2022, 12, 14), 'Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa', 0.2777633000855462], [datetime.date(2022, 12, 13), 'Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines', 0.5144454379482337], [datetime.date(2022, 12, 12), 'Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting', -1.1905372928391267], [datetime.date(2022, 12, 12), 'Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend', -1.1905372928391267], [datetime.date(2022, 12, 7), 'Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes', 0.6643536801099604], [datetime.date(2022, 12, 6), 'Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology', 1.3361333183020125], [datetime.date(2022, 12, 1), 'Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases', -0.008003692167022822], [datetime.date(2022, 11, 30), \"Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease\", 1.4203471925857263], [datetime.date(2022, 11, 30), 'Lilly and Akouos Announce Expiration of Akouos Tender Offer', 1.4203471925857263], [datetime.date(2022, 11, 29), 'Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement', 1.7408659271112261], [datetime.date(2022, 11, 21), 'Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium', 0.1357710242288256], [datetime.date(2022, 11, 16), 'Lilly to Participate in Evercore ISI HealthCONx Conference', 2.9852741809820893], [datetime.date(2022, 11, 7), 'Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform', 2.3618578930027803], [datetime.date(2022, 11, 4), 'Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease', -0.03560718962506887], [datetime.date(2022, 11, 3), 'Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting', 0.9372989552201737], [datetime.date(2022, 11, 1), 'Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress', 2.5721200946501046], [datetime.date(2022, 10, 27), 'Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration', 0.25284578662115315], [datetime.date(2022, 10, 19), 'Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement', -1.878010363156549], [datetime.date(2022, 10, 18), 'Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss', -1.4728779885558514], [datetime.date(2022, 10, 17), 'Lilly Declares Fourth-Quarter 2022 Dividend', 0.6685950724671748], [datetime.date(2022, 10, 6), 'Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities', -0.39184606778708125], [datetime.date(2022, 9, 21), \"FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type\", 3.1749600452482944], [datetime.date(2022, 9, 8), \"Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials\", 1.8098870160085119], [datetime.date(2022, 9, 7), 'Lilly Announces Details of Presentations at ESMO Congress 2022', 2.133120453138954], [datetime.date(2022, 8, 31), 'Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference', 0.6437450538576569], [datetime.date(2022, 8, 25), \"Lilly to Participate in Citi's 17th Annual BioPharma Conference\", -1.5971703182779382], [datetime.date(2022, 8, 11), 'Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly', 2.6063238555414276], [datetime.date(2022, 8, 8), \"Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience\", 0.782138203913299], [datetime.date(2022, 8, 4), 'Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results', -2.947047822036282], [datetime.date(2022, 8, 4), 'Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements', -2.947047822036282], [datetime.date(2022, 7, 21), 'Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement', 2.2205250188165917], [datetime.date(2022, 6, 29), 'Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options', 1.8721309669185282], [datetime.date(2022, 6, 27), 'Lilly Declares Third-Quarter 2022 Dividend', -2.081121053367924], [datetime.date(2022, 6, 13), \"FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata\", 0.12379312058463342], [datetime.date(2022, 6, 7), \"Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials\", 3.030404512024831], [datetime.date(2022, 6, 6), \"New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®\", -0.9708420916849521], [datetime.date(2022, 6, 5), 'Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study', -0.9708420916849521], [datetime.date(2022, 6, 4), \"Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo\", -0.9708420916849521], [datetime.date(2022, 6, 4), \"Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight\", -0.9708420916849521], [datetime.date(2022, 6, 3), 'Lilly to Participate in Goldman Sachs Global Healthcare Conference', 0.39556669541775735], [datetime.date(2022, 5, 26), 'Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting', 5.641772878398372], [datetime.date(2022, 5, 25), 'Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana', 2.060868798841787], [datetime.date(2022, 5, 24), \"Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study\", 1.0748860251922026], [datetime.date(2022, 5, 23), 'Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA', 1.751852875300683], [datetime.date(2022, 5, 20), \"CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)\", 3.9226629845775887], [datetime.date(2022, 5, 16), 'Lilly to Participate in UBS Global Healthcare Conference 2022', 3.082286411434026], [datetime.date(2022, 5, 13), \"FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes\", 2.2546649474292204], [datetime.date(2022, 5, 11), \"FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19\", 2.7861466985285457], [datetime.date(2022, 5, 6), 'Mary Lynne Hedley Elected to Lilly Board of Directors', -0.32499770991781674], [datetime.date(2022, 5, 3), 'Lilly to Participate in Bank of America Securities 2022 Healthcare Conference', 2.126150002436917], [datetime.date(2022, 5, 2), 'Lilly Declares Second-Quarter 2022 Dividend', -1.0969483152413997], [datetime.date(2022, 4, 28), \"Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022\", -1.3213391911635186], [datetime.date(2022, 4, 28), \"Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1\", -1.3213391911635186], [datetime.date(2022, 4, 20), 'Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care', -2.5586174456830766], [datetime.date(2022, 4, 19), 'Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement', -1.8742310890033445], [datetime.date(2022, 4, 11), \"Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis\", -1.6262059639210544], [datetime.date(2022, 4, 1), 'Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress', 1.8083989238519333], [datetime.date(2022, 3, 26), \"Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies\", -1.0194406427710274], [datetime.date(2022, 3, 26), \"Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies\", -1.0194406427710274], [datetime.date(2022, 3, 24), 'Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer', 0.9445790576834895], [datetime.date(2022, 3, 16), 'Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease', 2.682927885574432], [datetime.date(2022, 3, 8), 'Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)', 1.088339801087881], [datetime.date(2022, 3, 3), 'Lilly to Participate in Barclays Global Healthcare Conference', 3.058547747753866], [datetime.date(2022, 3, 1), 'Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial', 2.600627357040398], [datetime.date(2022, 2, 28), 'Lilly to Participate in Cowen Health Care Conference', 1.3466912095175478], [datetime.date(2022, 2, 24), 'US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction', 6.246763612611943], [datetime.date(2022, 2, 22), 'Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site', -0.3776694141710003], [datetime.date(2022, 2, 18), \"Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study\", 0.46417482851097613], [datetime.date(2022, 2, 16), 'Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence', -0.66813030557565], [datetime.date(2022, 2, 11), \"Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19\", -1.5107225438257998], [datetime.date(2022, 2, 10), 'Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options', -1.7646529157847102], [datetime.date(2022, 2, 10), 'Cynthia Cardona Elected as President of the Lilly Foundation', -1.7646529157847102], [datetime.date(2022, 2, 3), 'Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients', -2.1587401543947347], [datetime.date(2022, 2, 2), 'UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents', -0.22058035412364224], [datetime.date(2022, 2, 1), 'Lilly to Participate in Guggenheim Oncology Conference', 1.506995873785084], [datetime.date(2022, 1, 28), 'Lilly announces $1 billion investment in new manufacturing facility in North Carolina', 3.219373079947785], [datetime.date(2022, 1, 28), 'Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis', 3.219373079947785], [datetime.date(2022, 1, 20), 'Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement', -1.0367857554481936], [datetime.date(2022, 1, 6), 'Lilly to Participate in the J.P. Morgan Healthcare Conference', -0.23120617139011923], [datetime.date(2022, 1, 6), 'Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications', -0.23120617139011923], [datetime.date(2021, 12, 21), \"Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study\", 0.9380702946135364], [datetime.date(2021, 12, 15), 'Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting', 6.0815678414386305], [datetime.date(2021, 12, 14), 'Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022', 10.004346741141648], [datetime.date(2021, 12, 13), 'Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend', 1.5518607821196164], [datetime.date(2021, 12, 13), \"Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform\", 1.5518607821196164], [datetime.date(2021, 12, 12), 'Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting', 1.5518607821196164], [datetime.date(2021, 12, 10), 'Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders', 2.9493456516334633], [datetime.date(2021, 12, 9), 'New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients', -0.14337406855395698], [datetime.date(2021, 12, 3), \"Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12\", -2.354559145359978], [datetime.date(2021, 12, 1), 'Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting', -0.6293241922072789], [datetime.date(2021, 11, 18), 'Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients', -0.4986647972662094], [datetime.date(2021, 11, 17), 'Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference', 1.7296203661647365], [datetime.date(2021, 11, 11), 'US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction', -0.7013521513074406], [datetime.date(2021, 11, 11), 'Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care', -0.7013521513074406], [datetime.date(2021, 11, 9), 'Lilly to Participate in Wolfe Research Virtual Healthcare Conference', 1.5567646475447663], [datetime.date(2021, 11, 9), 'OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis', 1.5567646475447663], [datetime.date(2021, 11, 5), 'Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status', -3.2472243999742836], [datetime.date(2021, 11, 4), 'Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting', -0.18112592746395867], [datetime.date(2021, 11, 2), 'Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19', 5.637348000416161], [datetime.date(2021, 11, 1), \"Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference\", 0.6774419629776092], [datetime.date(2021, 10, 28), 'Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology', 1.8056052073166247], [datetime.date(2021, 10, 26), 'Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential', 2.2664593459062234], [datetime.date(2021, 10, 19), 'Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk', 1.912031654073653], [datetime.date(2021, 10, 18), 'Lilly Declares Fourth-Quarter 2021 Dividend', 1.7993439823016038], [datetime.date(2021, 10, 14), 'Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology', 0.36574043734877626], [datetime.date(2021, 10, 13), 'FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer', 1.1069321865402235], [datetime.date(2021, 10, 12), 'Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement', 0.7359089399600715], [datetime.date(2021, 10, 7), 'Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics', 2.0603574938990445], [datetime.date(2021, 10, 4), 'Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals', 1.355379492630161], [datetime.date(2021, 10, 1), 'At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study', -2.7351490838861734], [datetime.date(2021, 9, 30), 'OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata', -1.3894346458519264], [datetime.date(2021, 9, 30), \"Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study\", -1.3894346458519264], [datetime.date(2021, 9, 30), \"Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study\", -1.3894346458519264], [datetime.date(2021, 9, 29), 'Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women', 2.4410264011323326], [datetime.date(2021, 9, 28), \"FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy\", 1.723390798325766], [datetime.date(2021, 9, 28), 'Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options', 1.723390798325766], [datetime.date(2021, 9, 27), 'New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary', -3.7770759406685914], [datetime.date(2021, 9, 24), 'Eli Lilly and Company\\u202fIssues Voluntary\\u202fNationwide Recall of\\u202fOne Lot of GLUCAGON® Emergency Kit Due\\u202fto Loss of Potency', -2.813599803358029], [datetime.date(2021, 9, 21), 'Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities', -1.6469554230164933], [datetime.date(2021, 9, 21), 'Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19', -1.6469554230164933], [datetime.date(2021, 9, 21), 'Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059', -1.6469554230164933], [datetime.date(2021, 9, 16), \"Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19\", -1.729692120557489], [datetime.date(2021, 9, 15), 'Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19', -1.099372905045263], [datetime.date(2021, 9, 13), 'Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference', -2.981682457560067], [datetime.date(2021, 9, 13), 'Lilly to Present New Data from Oncology Portfolio at ESMO Congress', -2.981682457560067], [datetime.date(2021, 9, 9), 'Lilly Prices First Sustainability Bond to Advance Global ESG Strategy', -5.75781467833885], [datetime.date(2021, 9, 9), 'FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction', -5.75781467833885], [datetime.date(2021, 9, 7), 'Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to \"Type 1 Diabetes Camps Initiative\"', -1.6324043487380548], [datetime.date(2021, 9, 7), 'Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities', -1.6324043487380548], [datetime.date(2021, 9, 3), 'Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference', -2.366551093120754], [datetime.date(2021, 8, 31), \"Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference\", -2.113447081259668], [datetime.date(2021, 8, 27), 'Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction', -0.08005011139647274], [datetime.date(2021, 8, 25), 'Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders', -0.5587033137737072], [datetime.date(2021, 8, 25), 'Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors', -0.5587033137737072], [datetime.date(2021, 8, 18), 'US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction', -0.5954356702913074], [datetime.date(2021, 8, 17), 'Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units', -0.9831604122598897], [datetime.date(2021, 8, 16), 'FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps', 2.8711821939552475], [datetime.date(2021, 8, 16), \"Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials\", 2.8711821939552475], [datetime.date(2021, 8, 3), 'Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance', 6.751260488686206], [datetime.date(2021, 8, 3), \"Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation\", 6.751260488686206], [datetime.date(2021, 7, 29), 'Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline', -1.64270149837966], [datetime.date(2021, 7, 29), \"FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen\", -1.64270149837966], [datetime.date(2021, 7, 29), 'Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses', -1.64270149837966], [datetime.date(2021, 7, 22), 'Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement', 2.8138425413153314], [datetime.date(2021, 7, 16), 'Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis', 0.700438682551326], [datetime.date(2021, 7, 15), \"Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab\", -1.0969686845301976], [datetime.date(2021, 7, 14), 'Lilly Announces Acquisition of Protomer Technologies', -1.866324498749989], [datetime.date(2021, 7, 9), 'Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study', -0.4915090146513157], [datetime.date(2021, 7, 6), 'Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction', 0.9286819188931776], [datetime.date(2021, 6, 29), 'Lilly Declares Third-Quarter 2021 Dividend', 0.5533246462590827], [datetime.date(2021, 6, 26), \"Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes\", 0.1613061791243181], [datetime.date(2021, 6, 25), \"Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes\", -2.1470475153989685], [datetime.date(2021, 6, 24), 'Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin', -2.0415135576723724], [datetime.date(2021, 6, 24), \"Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease\", -2.0415135576723724], [datetime.date(2021, 6, 17), 'Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine', -0.7870146812041756], [datetime.date(2021, 6, 15), 'Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine', -2.4189186065559225], [datetime.date(2021, 6, 14), 'Lilly to Participate in Guggenheim Biopharma Strategy Series', -0.3176495061632742], [datetime.date(2021, 6, 11), 'Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA', -0.4113194013479604], [datetime.date(2021, 6, 4), 'Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting', 8.86662745021121], [datetime.date(2021, 6, 3), 'Lilly to Participate in Goldman Sachs Healthcare Conference', 1.4998428843014826], [datetime.date(2021, 6, 3), \"Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021\", 1.4998428843014826], [datetime.date(2021, 6, 1), 'OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses', -0.5975984683042826], [datetime.date(2021, 6, 1), 'Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study', -0.5975984683042826], [datetime.date(2021, 5, 22), \"Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial\", -0.8934713180470056], [datetime.date(2021, 5, 20), \"Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial\", 1.3608218002768524], [datetime.date(2021, 5, 19), 'Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting', 2.966959784987537], [datetime.date(2021, 5, 18), 'U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer', 0.7684295422907699], [datetime.date(2021, 5, 13), 'Lilly to Participate in UBS Global Healthcare Virtual Conference', 2.018252692983907], [datetime.date(2021, 5, 11), 'Lilly and MiNA Therapeutics Announce saRNA Research Collaboration', -0.09834628654598798], [datetime.date(2021, 5, 6), 'Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes', 1.9803426507996016], [datetime.date(2021, 5, 5), 'Lilly to Participate in Bank of America Securities 2021 Health Care Conference', 2.702560391803232], [datetime.date(2021, 5, 4), 'Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries', 2.73844585352178], [datetime.date(2021, 5, 4), 'Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe', 2.73844585352178], [datetime.date(2021, 5, 4), \"Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements\", 2.73844585352178], [datetime.date(2021, 5, 3), 'Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization', 2.768328897627359], [datetime.date(2021, 5, 3), \"Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity\", 2.768328897627359], [datetime.date(2021, 4, 27), 'Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance', -1.910834873331636], [datetime.date(2021, 4, 23), 'OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses', 0.10148871488248096], [datetime.date(2021, 4, 23), 'Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis', 0.10148871488248096], [datetime.date(2021, 4, 20), \"Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study\", 0.2827872919770121], [datetime.date(2021, 4, 16), 'Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.', 1.1917105001683848], [datetime.date(2021, 4, 13), 'Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer', 0.9945386617059435], [datetime.date(2021, 4, 12), 'Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together', -0.49306390582812043], [datetime.date(2021, 4, 11), 'Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting', -0.49306390582812043], [datetime.date(2021, 4, 8), 'Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients', 0.834743200318689], [datetime.date(2021, 4, 6), 'Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis', -1.299898879113727], [datetime.date(2021, 4, 6), 'Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement', -1.299898879113727], [datetime.date(2021, 4, 1), 'Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts', -1.0438614518929892], [datetime.date(2021, 3, 31), 'Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care', -0.17814699333830097], [datetime.date(2021, 3, 29), 'Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19', 0.45282089466448805], [datetime.date(2021, 3, 25), 'Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain', 2.3258384219311328], [datetime.date(2021, 3, 17), 'Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021', -3.153363129714877], [datetime.date(2021, 3, 16), \"Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study\", -2.57593351152086], [datetime.date(2021, 3, 13), \"Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM\", -1.1052821150877878], [datetime.date(2021, 3, 10), 'Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)', -0.8186651425700494], [datetime.date(2021, 3, 10), \"Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19\", -0.8186651425700494], [datetime.date(2021, 3, 9), \"Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research\", -1.4066590318658079], [datetime.date(2021, 3, 9), 'Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations', -1.4066590318658079], [datetime.date(2021, 3, 8), 'Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes', -0.4318156242682604], [datetime.date(2021, 3, 8), 'Lilly to Participate in Barclays Global Healthcare Conference', -0.4318156242682604], [datetime.date(2021, 3, 5), \"EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union\", 2.90295686034795], [datetime.date(2021, 3, 5), 'Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet', 2.90295686034795], [datetime.date(2021, 3, 4), 'Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes', 1.5126696324658429], [datetime.date(2021, 3, 3), 'Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial', -1.4111998480669676], [datetime.date(2021, 2, 26), 'Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19', -0.11139543551724157], [datetime.date(2021, 2, 25), \"Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions\", 0.6442394155306825], [datetime.date(2021, 2, 24), 'Lilly to Participate in Cowen Health Care Conference', 1.0548538092801831], [datetime.date(2021, 2, 18), 'Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases', -2.179973163925526], [datetime.date(2021, 2, 17), \"Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program\", -1.9341686539256917], [datetime.date(2021, 2, 17), 'Kimberly H. Johnson Elected to Lilly Board of Directors', -1.9341686539256917], [datetime.date(2021, 2, 11), 'Lilly To Participate in SVB Leerink Global Healthcare Conference', 2.1322912228991826], [datetime.date(2021, 2, 9), \"Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19\", 0.3131370516048955], [datetime.date(2021, 2, 9), 'Lilly Appoints Anat Ashkenazi Chief Financial Officer', 0.3131370516048955], [datetime.date(2021, 2, 4), \"Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference\", 2.458248996653258], [datetime.date(2021, 2, 3), 'Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day', 1.8896904419385896], [datetime.date(2021, 2, 1), 'Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients', -6.023480333134452], [datetime.date(2021, 1, 29), 'Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results', -4.341852826107324], [datetime.date(2021, 1, 28), 'Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate', -0.014406578260303551], [datetime.date(2021, 1, 27), 'Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19', -0.45214890499253063], [datetime.date(2021, 1, 26), \"New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death  by 70 percent\", -2.3991832462259755], [datetime.date(2021, 1, 22), 'Lilly Completes Acquisition of Prevail Therapeutics', 4.855196902631354], [datetime.date(2021, 1, 21), \"Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents\", 1.183651804239554], [datetime.date(2021, 1, 19), 'Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies', 2.613545831981336], [datetime.date(2021, 1, 15), 'Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement', 5.884722120248119], [datetime.date(2021, 1, 15), 'Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund', 5.884722120248119], [datetime.date(2021, 1, 14), 'Gabrielle Sulzberger Elected to Lilly Board of Directors', 2.8830392049234477], [datetime.date(2021, 1, 11), 'US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction', -3.4675533355369486], [datetime.date(2021, 1, 11), \"Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial\", -3.4675533355369486], [datetime.date(2021, 1, 4), 'Lilly to Participate in J.P. Morgan Healthcare Conference', -1.6233699696555335], [datetime.date(2020, 12, 18), 'Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico', -2.2158973629934664], [datetime.date(2020, 12, 15), 'Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance', 7.335088466876838], [datetime.date(2020, 12, 15), 'Lilly Announces Agreement to Acquire Prevail Therapeutics', 7.335088466876838], [datetime.date(2020, 12, 14), 'Lilly Announces 15 Percent Dividend Increase', 4.025542271098061], [datetime.date(2020, 12, 14), 'Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study', 4.025542271098061], [datetime.date(2020, 12, 11), 'Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine', -1.1462061178501555], [datetime.date(2020, 12, 9), 'Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®', 3.9813758694087564], [datetime.date(2020, 12, 9), \"Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes\", 3.9813758694087564], [datetime.date(2020, 12, 8), 'Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement', 6.974676396661185], [datetime.date(2020, 12, 7), 'Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting', 1.3395846311477841], [datetime.date(2020, 12, 5), 'Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting', 1.3395846311477841], [datetime.date(2020, 12, 4), 'Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19', 2.2724140918249276], [datetime.date(2020, 12, 2), 'Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19', -0.8673925409195257], [datetime.date(2020, 11, 24), 'Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference', 0.9395392643179388], [datetime.date(2020, 11, 20), \"Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19\", 0.37662251521238244], [datetime.date(2020, 11, 20), 'Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement', 0.37662251521238244], [datetime.date(2020, 11, 19), 'Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19', 3.6016239621666437], [datetime.date(2020, 11, 19), 'Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes', 3.6016239621666437], [datetime.date(2020, 11, 18), 'Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial', 1.052940398784301], [datetime.date(2020, 11, 12), 'Lilly to Participate in Wolfe Research Virtual Healthcare Conference', -0.386301257754524], [datetime.date(2020, 11, 12), 'Lilly to Participate in Bernstein Operational Decisions Conference', -0.386301257754524], [datetime.date(2020, 11, 11), 'Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program', -4.236432488985899], [datetime.date(2020, 11, 9), \"Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19\", 2.7429084371914207], [datetime.date(2020, 11, 5), 'Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting', -3.4608281630830553], [datetime.date(2020, 11, 5), 'Aarti Shah to Retire as Lilly Chief Information and Digital Officer', -3.4608281630830553], [datetime.date(2020, 11, 2), 'ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis', -1.1910101910440951], [datetime.date(2020, 10, 31), 'EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis', -1.1910101910440951], [datetime.date(2020, 10, 30), 'Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata', -0.0987761903529434], [datetime.date(2020, 10, 29), 'New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis', -1.180440383900482], [datetime.date(2020, 10, 28), \"Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine\", 1.576762641645986], [datetime.date(2020, 10, 28), 'Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19', 1.576762641645986], [datetime.date(2020, 10, 27), 'Lilly Reports Third-Quarter Financial Results, Updates Guidance', -1.3022542566823285], [datetime.date(2020, 10, 23), 'New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status', -0.3810992525862045], [datetime.date(2020, 10, 19), 'Lilly Declares Fourth-Quarter 2020 Dividend', -2.3748287132920374], [datetime.date(2020, 10, 15), 'Lilly Announces Agreement to Acquire Disarm Therapeutics', -0.2669142463667253], [datetime.date(2020, 10, 12), \"Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial\", -4.497594377955216], [datetime.date(2020, 10, 9), \"Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment\", 0.25890970895060506], [datetime.date(2020, 10, 8), 'Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement', 2.855685002735844], [datetime.date(2020, 10, 8), 'Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen', 2.855685002735844], [datetime.date(2020, 10, 8), 'Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity', 2.855685002735844], [datetime.date(2020, 10, 8), 'Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries', 2.855685002735844], [datetime.date(2020, 10, 7), 'Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs', 3.2442921076688744], [datetime.date(2020, 10, 7), 'Lilly and Dexcom team up on new program to help improve diabetes management', 3.2442921076688744], [datetime.date(2020, 10, 6), 'REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study', 1.3628170993610822], [datetime.date(2020, 9, 20), 'Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer', -2.208725914529043], [datetime.date(2020, 9, 18), \"CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis\", -0.5688639831000171]]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[datetime.date(2023, 4, 27), 'Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum', None], [datetime.date(2023, 4, 27), \"Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2\", None], [datetime.date(2023, 4, 24), 'Lilly to Divest BAQSIMI to Amphastar', -0.10393771445033984], [datetime.date(2023, 4, 17), 'Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities', -1.3760093772808675], [datetime.date(2023, 4, 13), 'U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab', 0.563076296874874], [datetime.date(2023, 4, 13), 'Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement', 0.563076296874874], [datetime.date(2023, 3, 14), 'Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting', 1.645070388093893], [datetime.date(2023, 3, 8), \"Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease\", 2.004104775507267], [datetime.date(2023, 3, 8), 'US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes', 2.004104775507267], [datetime.date(2023, 3, 6), 'Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study', -2.0313548142183637], [datetime.date(2023, 3, 3), 'U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer', 0.8120129192615044], [datetime.date(2023, 3, 1), 'Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month', 1.602916358875496], [datetime.date(2023, 2, 21), \"Lilly to Participate in Cowen's 43rd Annual Health Care Conference\", 0.5834665527091526], [datetime.date(2023, 2, 13), 'Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh', 0.6350924742413218], [datetime.date(2023, 2, 7), 'Lilly to Participate in SVB Securities Global Biopharma Conference', 1.3735279522019026], [datetime.date(2023, 2, 3), 'Lilly to Participate in Guggenheim Oncology Conference', 1.3948912300949747], [datetime.date(2023, 2, 2), 'Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook', 1.4981634905367671], [datetime.date(2023, 1, 27), 'U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor', -1.6475735096717476], [datetime.date(2023, 1, 26), \"Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity\", -2.601572434644426], [datetime.date(2023, 1, 24), 'Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park', 1.066539689439987], [datetime.date(2023, 1, 20), 'US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease', -1.3997270099784656], [datetime.date(2023, 1, 19), 'U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab', -1.8204412062687716], [datetime.date(2023, 1, 19), 'Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement', -1.8204412062687716], [datetime.date(2023, 1, 4), 'Lilly to Participate in the J.P. Morgan Healthcare Conference', -1.5936676996874373], [datetime.date(2022, 12, 22), 'Lilly and ProQR to Expand RNA Editing Collaboration', 0.15765367903162142], [datetime.date(2022, 12, 14), 'Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa', 0.2777633000855462], [datetime.date(2022, 12, 13), 'Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines', 0.5144454379482337], [datetime.date(2022, 12, 12), 'Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting', -1.1905372928391267], [datetime.date(2022, 12, 12), 'Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend', -1.1905372928391267], [datetime.date(2022, 12, 7), 'Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes', 0.6643536801099604], [datetime.date(2022, 12, 6), 'Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology', 1.3361333183020125], [datetime.date(2022, 12, 1), 'Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases', -0.008003692167022822], [datetime.date(2022, 11, 30), \"Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease\", 1.4203471925857263], [datetime.date(2022, 11, 30), 'Lilly and Akouos Announce Expiration of Akouos Tender Offer', 1.4203471925857263], [datetime.date(2022, 11, 29), 'Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement', 1.7408659271112261], [datetime.date(2022, 11, 21), 'Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium', 0.1357710242288256], [datetime.date(2022, 11, 16), 'Lilly to Participate in Evercore ISI HealthCONx Conference', 2.9852741809820893], [datetime.date(2022, 11, 7), 'Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform', 2.3618578930027803], [datetime.date(2022, 11, 4), 'Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease', -0.03560718962506887], [datetime.date(2022, 11, 3), 'Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting', 0.9372989552201737], [datetime.date(2022, 11, 1), 'Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress', 2.5721200946501046], [datetime.date(2022, 10, 27), 'Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration', 0.25284578662115315], [datetime.date(2022, 10, 19), 'Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement', -1.878010363156549], [datetime.date(2022, 10, 18), 'Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss', -1.4728779885558514], [datetime.date(2022, 10, 17), 'Lilly Declares Fourth-Quarter 2022 Dividend', 0.6685950724671748], [datetime.date(2022, 10, 6), 'Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities', -0.39184606778708125], [datetime.date(2022, 9, 21), \"FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type\", 3.1749600452482944], [datetime.date(2022, 9, 8), \"Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials\", 1.8098870160085119], [datetime.date(2022, 9, 7), 'Lilly Announces Details of Presentations at ESMO Congress 2022', 2.133120453138954], [datetime.date(2022, 8, 31), 'Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference', 0.6437450538576569], [datetime.date(2022, 8, 25), \"Lilly to Participate in Citi's 17th Annual BioPharma Conference\", -1.5971703182779382], [datetime.date(2022, 8, 11), 'Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly', 2.6063238555414276], [datetime.date(2022, 8, 8), \"Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience\", 0.782138203913299], [datetime.date(2022, 8, 4), 'Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results', -2.947047822036282], [datetime.date(2022, 8, 4), 'Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements', -2.947047822036282], [datetime.date(2022, 7, 21), 'Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement', 2.2205250188165917], [datetime.date(2022, 6, 29), 'Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options', 1.8721309669185282], [datetime.date(2022, 6, 27), 'Lilly Declares Third-Quarter 2022 Dividend', -2.081121053367924], [datetime.date(2022, 6, 13), \"FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata\", 0.12379312058463342], [datetime.date(2022, 6, 7), \"Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials\", 3.030404512024831], [datetime.date(2022, 6, 6), \"New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®\", -0.9708420916849521], [datetime.date(2022, 6, 5), 'Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study', -0.9708420916849521], [datetime.date(2022, 6, 4), \"Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo\", -0.9708420916849521], [datetime.date(2022, 6, 4), \"Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight\", -0.9708420916849521], [datetime.date(2022, 6, 3), 'Lilly to Participate in Goldman Sachs Global Healthcare Conference', 0.39556669541775735], [datetime.date(2022, 5, 26), 'Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting', 5.641772878398372], [datetime.date(2022, 5, 25), 'Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana', 2.060868798841787], [datetime.date(2022, 5, 24), \"Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study\", 1.0748860251922026], [datetime.date(2022, 5, 23), 'Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA', 1.751852875300683], [datetime.date(2022, 5, 20), \"CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)\", 3.9226629845775887], [datetime.date(2022, 5, 16), 'Lilly to Participate in UBS Global Healthcare Conference 2022', 3.082286411434026], [datetime.date(2022, 5, 13), \"FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes\", 2.2546649474292204], [datetime.date(2022, 5, 11), \"FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19\", 2.7861466985285457], [datetime.date(2022, 5, 6), 'Mary Lynne Hedley Elected to Lilly Board of Directors', -0.32499770991781674], [datetime.date(2022, 5, 3), 'Lilly to Participate in Bank of America Securities 2022 Healthcare Conference', 2.126150002436917], [datetime.date(2022, 5, 2), 'Lilly Declares Second-Quarter 2022 Dividend', -1.0969483152413997], [datetime.date(2022, 4, 28), \"Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022\", -1.3213391911635186], [datetime.date(2022, 4, 28), \"Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1\", -1.3213391911635186], [datetime.date(2022, 4, 20), 'Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care', -2.5586174456830766], [datetime.date(2022, 4, 19), 'Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement', -1.8742310890033445], [datetime.date(2022, 4, 11), \"Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis\", -1.6262059639210544], [datetime.date(2022, 4, 1), 'Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress', 1.8083989238519333], [datetime.date(2022, 3, 26), \"Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies\", -1.0194406427710274], [datetime.date(2022, 3, 26), \"Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies\", -1.0194406427710274], [datetime.date(2022, 3, 24), 'Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer', 0.9445790576834895], [datetime.date(2022, 3, 16), 'Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease', 2.682927885574432], [datetime.date(2022, 3, 8), 'Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)', 1.088339801087881], [datetime.date(2022, 3, 3), 'Lilly to Participate in Barclays Global Healthcare Conference', 3.058547747753866], [datetime.date(2022, 3, 1), 'Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial', 2.600627357040398], [datetime.date(2022, 2, 28), 'Lilly to Participate in Cowen Health Care Conference', 1.3466912095175478], [datetime.date(2022, 2, 24), 'US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction', 6.246763612611943], [datetime.date(2022, 2, 22), 'Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site', -0.3776694141710003], [datetime.date(2022, 2, 18), \"Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study\", 0.46417482851097613], [datetime.date(2022, 2, 16), 'Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence', -0.66813030557565], [datetime.date(2022, 2, 11), \"Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19\", -1.5107225438257998], [datetime.date(2022, 2, 10), 'Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options', -1.7646529157847102], [datetime.date(2022, 2, 10), 'Cynthia Cardona Elected as President of the Lilly Foundation', -1.7646529157847102], [datetime.date(2022, 2, 3), 'Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients', -2.1587401543947347], [datetime.date(2022, 2, 2), 'UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents', -0.22058035412364224], [datetime.date(2022, 2, 1), 'Lilly to Participate in Guggenheim Oncology Conference', 1.506995873785084], [datetime.date(2022, 1, 28), 'Lilly announces $1 billion investment in new manufacturing facility in North Carolina', 3.219373079947785], [datetime.date(2022, 1, 28), 'Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis', 3.219373079947785], [datetime.date(2022, 1, 20), 'Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement', -1.0367857554481936], [datetime.date(2022, 1, 6), 'Lilly to Participate in the J.P. Morgan Healthcare Conference', -0.23120617139011923], [datetime.date(2022, 1, 6), 'Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications', -0.23120617139011923], [datetime.date(2021, 12, 21), \"Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study\", 0.9380702946135364], [datetime.date(2021, 12, 15), 'Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting', 6.0815678414386305], [datetime.date(2021, 12, 14), 'Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022', 10.004346741141648], [datetime.date(2021, 12, 13), 'Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend', 1.5518607821196164], [datetime.date(2021, 12, 13), \"Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform\", 1.5518607821196164], [datetime.date(2021, 12, 12), 'Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting', 1.5518607821196164], [datetime.date(2021, 12, 10), 'Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders', 2.9493456516334633], [datetime.date(2021, 12, 9), 'New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients', -0.14337406855395698], [datetime.date(2021, 12, 3), \"Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12\", -2.354559145359978], [datetime.date(2021, 12, 1), 'Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting', -0.6293241922072789], [datetime.date(2021, 11, 18), 'Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients', -0.4986647972662094], [datetime.date(2021, 11, 17), 'Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference', 1.7296203661647365], [datetime.date(2021, 11, 11), 'US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction', -0.7013521513074406], [datetime.date(2021, 11, 11), 'Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care', -0.7013521513074406], [datetime.date(2021, 11, 9), 'Lilly to Participate in Wolfe Research Virtual Healthcare Conference', 1.5567646475447663], [datetime.date(2021, 11, 9), 'OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis', 1.5567646475447663], [datetime.date(2021, 11, 5), 'Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status', -3.2472243999742836], [datetime.date(2021, 11, 4), 'Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting', -0.18112592746395867], [datetime.date(2021, 11, 2), 'Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19', 5.637348000416161], [datetime.date(2021, 11, 1), \"Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference\", 0.6774419629776092], [datetime.date(2021, 10, 28), 'Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology', 1.8056052073166247], [datetime.date(2021, 10, 26), 'Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential', 2.2664593459062234], [datetime.date(2021, 10, 19), 'Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk', 1.912031654073653], [datetime.date(2021, 10, 18), 'Lilly Declares Fourth-Quarter 2021 Dividend', 1.7993439823016038], [datetime.date(2021, 10, 14), 'Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology', 0.36574043734877626], [datetime.date(2021, 10, 13), 'FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer', 1.1069321865402235], [datetime.date(2021, 10, 12), 'Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement', 0.7359089399600715], [datetime.date(2021, 10, 7), 'Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics', 2.0603574938990445], [datetime.date(2021, 10, 4), 'Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals', 1.355379492630161], [datetime.date(2021, 10, 1), 'At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study', -2.7351490838861734], [datetime.date(2021, 9, 30), 'OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata', -1.3894346458519264], [datetime.date(2021, 9, 30), \"Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study\", -1.3894346458519264], [datetime.date(2021, 9, 30), \"Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study\", -1.3894346458519264], [datetime.date(2021, 9, 29), 'Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women', 2.4410264011323326], [datetime.date(2021, 9, 28), \"FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy\", 1.723390798325766], [datetime.date(2021, 9, 28), 'Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options', 1.723390798325766], [datetime.date(2021, 9, 27), 'New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary', -3.7770759406685914], [datetime.date(2021, 9, 24), 'Eli Lilly and Company\\u202fIssues Voluntary\\u202fNationwide Recall of\\u202fOne Lot of GLUCAGON® Emergency Kit Due\\u202fto Loss of Potency', -2.813599803358029], [datetime.date(2021, 9, 21), 'Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities', -1.6469554230164933], [datetime.date(2021, 9, 21), 'Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19', -1.6469554230164933], [datetime.date(2021, 9, 21), 'Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059', -1.6469554230164933], [datetime.date(2021, 9, 16), \"Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19\", -1.729692120557489], [datetime.date(2021, 9, 15), 'Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19', -1.099372905045263], [datetime.date(2021, 9, 13), 'Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference', -2.981682457560067], [datetime.date(2021, 9, 13), 'Lilly to Present New Data from Oncology Portfolio at ESMO Congress', -2.981682457560067], [datetime.date(2021, 9, 9), 'Lilly Prices First Sustainability Bond to Advance Global ESG Strategy', -5.75781467833885], [datetime.date(2021, 9, 9), 'FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction', -5.75781467833885], [datetime.date(2021, 9, 7), 'Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to \"Type 1 Diabetes Camps Initiative\"', -1.6324043487380548], [datetime.date(2021, 9, 7), 'Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities', -1.6324043487380548], [datetime.date(2021, 9, 3), 'Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference', -2.366551093120754], [datetime.date(2021, 8, 31), \"Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference\", -2.113447081259668], [datetime.date(2021, 8, 27), 'Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction', -0.08005011139647274], [datetime.date(2021, 8, 25), 'Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders', -0.5587033137737072], [datetime.date(2021, 8, 25), 'Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors', -0.5587033137737072], [datetime.date(2021, 8, 18), 'US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction', -0.5954356702913074], [datetime.date(2021, 8, 17), 'Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units', -0.9831604122598897], [datetime.date(2021, 8, 16), 'FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps', 2.8711821939552475], [datetime.date(2021, 8, 16), \"Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials\", 2.8711821939552475], [datetime.date(2021, 8, 3), 'Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance', 6.751260488686206], [datetime.date(2021, 8, 3), \"Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation\", 6.751260488686206], [datetime.date(2021, 7, 29), 'Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline', -1.64270149837966], [datetime.date(2021, 7, 29), \"FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen\", -1.64270149837966], [datetime.date(2021, 7, 29), 'Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses', -1.64270149837966], [datetime.date(2021, 7, 22), 'Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement', 2.8138425413153314], [datetime.date(2021, 7, 16), 'Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis', 0.700438682551326], [datetime.date(2021, 7, 15), \"Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab\", -1.0969686845301976], [datetime.date(2021, 7, 14), 'Lilly Announces Acquisition of Protomer Technologies', -1.866324498749989], [datetime.date(2021, 7, 9), 'Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study', -0.4915090146513157], [datetime.date(2021, 7, 6), 'Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction', 0.9286819188931776], [datetime.date(2021, 6, 29), 'Lilly Declares Third-Quarter 2021 Dividend', 0.5533246462590827], [datetime.date(2021, 6, 26), \"Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes\", 0.1613061791243181], [datetime.date(2021, 6, 25), \"Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes\", -2.1470475153989685], [datetime.date(2021, 6, 24), 'Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin', -2.0415135576723724], [datetime.date(2021, 6, 24), \"Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease\", -2.0415135576723724], [datetime.date(2021, 6, 17), 'Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine', -0.7870146812041756], [datetime.date(2021, 6, 15), 'Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine', -2.4189186065559225], [datetime.date(2021, 6, 14), 'Lilly to Participate in Guggenheim Biopharma Strategy Series', -0.3176495061632742], [datetime.date(2021, 6, 11), 'Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA', -0.4113194013479604], [datetime.date(2021, 6, 4), 'Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting', 8.86662745021121], [datetime.date(2021, 6, 3), 'Lilly to Participate in Goldman Sachs Healthcare Conference', 1.4998428843014826], [datetime.date(2021, 6, 3), \"Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021\", 1.4998428843014826], [datetime.date(2021, 6, 1), 'OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses', -0.5975984683042826], [datetime.date(2021, 6, 1), 'Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study', -0.5975984683042826], [datetime.date(2021, 5, 22), \"Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial\", -0.8934713180470056], [datetime.date(2021, 5, 20), \"Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial\", 1.3608218002768524], [datetime.date(2021, 5, 19), 'Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting', 2.966959784987537], [datetime.date(2021, 5, 18), 'U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer', 0.7684295422907699], [datetime.date(2021, 5, 13), 'Lilly to Participate in UBS Global Healthcare Virtual Conference', 2.018252692983907], [datetime.date(2021, 5, 11), 'Lilly and MiNA Therapeutics Announce saRNA Research Collaboration', -0.09834628654598798], [datetime.date(2021, 5, 6), 'Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes', 1.9803426507996016], [datetime.date(2021, 5, 5), 'Lilly to Participate in Bank of America Securities 2021 Health Care Conference', 2.702560391803232], [datetime.date(2021, 5, 4), 'Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries', 2.73844585352178], [datetime.date(2021, 5, 4), 'Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe', 2.73844585352178], [datetime.date(2021, 5, 4), \"Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements\", 2.73844585352178], [datetime.date(2021, 5, 3), 'Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization', 2.768328897627359], [datetime.date(2021, 5, 3), \"Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity\", 2.768328897627359], [datetime.date(2021, 4, 27), 'Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance', -1.910834873331636], [datetime.date(2021, 4, 23), 'OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses', 0.10148871488248096], [datetime.date(2021, 4, 23), 'Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis', 0.10148871488248096], [datetime.date(2021, 4, 20), \"Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study\", 0.2827872919770121], [datetime.date(2021, 4, 16), 'Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.', 1.1917105001683848], [datetime.date(2021, 4, 13), 'Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer', 0.9945386617059435], [datetime.date(2021, 4, 12), 'Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together', -0.49306390582812043], [datetime.date(2021, 4, 11), 'Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting', -0.49306390582812043], [datetime.date(2021, 4, 8), 'Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients', 0.834743200318689], [datetime.date(2021, 4, 6), 'Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis', -1.299898879113727], [datetime.date(2021, 4, 6), 'Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement', -1.299898879113727], [datetime.date(2021, 4, 1), 'Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts', -1.0438614518929892], [datetime.date(2021, 3, 31), 'Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care', -0.17814699333830097], [datetime.date(2021, 3, 29), 'Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19', 0.45282089466448805], [datetime.date(2021, 3, 25), 'Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain', 2.3258384219311328], [datetime.date(2021, 3, 17), 'Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021', -3.153363129714877], [datetime.date(2021, 3, 16), \"Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study\", -2.57593351152086], [datetime.date(2021, 3, 13), \"Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM\", -1.1052821150877878], [datetime.date(2021, 3, 10), 'Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)', -0.8186651425700494], [datetime.date(2021, 3, 10), \"Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19\", -0.8186651425700494], [datetime.date(2021, 3, 9), \"Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research\", -1.4066590318658079], [datetime.date(2021, 3, 9), 'Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations', -1.4066590318658079], [datetime.date(2021, 3, 8), 'Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes', -0.4318156242682604], [datetime.date(2021, 3, 8), 'Lilly to Participate in Barclays Global Healthcare Conference', -0.4318156242682604], [datetime.date(2021, 3, 5), \"EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union\", 2.90295686034795], [datetime.date(2021, 3, 5), 'Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet', 2.90295686034795], [datetime.date(2021, 3, 4), 'Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes', 1.5126696324658429], [datetime.date(2021, 3, 3), 'Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial', -1.4111998480669676], [datetime.date(2021, 2, 26), 'Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19', -0.11139543551724157], [datetime.date(2021, 2, 25), \"Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions\", 0.6442394155306825], [datetime.date(2021, 2, 24), 'Lilly to Participate in Cowen Health Care Conference', 1.0548538092801831], [datetime.date(2021, 2, 18), 'Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases', -2.179973163925526], [datetime.date(2021, 2, 17), \"Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program\", -1.9341686539256917], [datetime.date(2021, 2, 17), 'Kimberly H. Johnson Elected to Lilly Board of Directors', -1.9341686539256917], [datetime.date(2021, 2, 11), 'Lilly To Participate in SVB Leerink Global Healthcare Conference', 2.1322912228991826], [datetime.date(2021, 2, 9), \"Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19\", 0.3131370516048955], [datetime.date(2021, 2, 9), 'Lilly Appoints Anat Ashkenazi Chief Financial Officer', 0.3131370516048955], [datetime.date(2021, 2, 4), \"Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference\", 2.458248996653258], [datetime.date(2021, 2, 3), 'Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day', 1.8896904419385896], [datetime.date(2021, 2, 1), 'Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients', -6.023480333134452], [datetime.date(2021, 1, 29), 'Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results', -4.341852826107324], [datetime.date(2021, 1, 28), 'Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate', -0.014406578260303551], [datetime.date(2021, 1, 27), 'Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19', -0.45214890499253063], [datetime.date(2021, 1, 26), \"New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death  by 70 percent\", -2.3991832462259755], [datetime.date(2021, 1, 22), 'Lilly Completes Acquisition of Prevail Therapeutics', 4.855196902631354], [datetime.date(2021, 1, 21), \"Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents\", 1.183651804239554], [datetime.date(2021, 1, 19), 'Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies', 2.613545831981336], [datetime.date(2021, 1, 15), 'Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement', 5.884722120248119], [datetime.date(2021, 1, 15), 'Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund', 5.884722120248119], [datetime.date(2021, 1, 14), 'Gabrielle Sulzberger Elected to Lilly Board of Directors', 2.8830392049234477], [datetime.date(2021, 1, 11), 'US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction', -3.4675533355369486], [datetime.date(2021, 1, 11), \"Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial\", -3.4675533355369486], [datetime.date(2021, 1, 4), 'Lilly to Participate in J.P. Morgan Healthcare Conference', -1.6233699696555335], [datetime.date(2020, 12, 18), 'Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico', -2.2158973629934664], [datetime.date(2020, 12, 15), 'Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance', 7.335088466876838], [datetime.date(2020, 12, 15), 'Lilly Announces Agreement to Acquire Prevail Therapeutics', 7.335088466876838], [datetime.date(2020, 12, 14), 'Lilly Announces 15 Percent Dividend Increase', 4.025542271098061], [datetime.date(2020, 12, 14), 'Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study', 4.025542271098061], [datetime.date(2020, 12, 11), 'Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine', -1.1462061178501555], [datetime.date(2020, 12, 9), 'Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®', 3.9813758694087564], [datetime.date(2020, 12, 9), \"Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes\", 3.9813758694087564], [datetime.date(2020, 12, 8), 'Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement', 6.974676396661185], [datetime.date(2020, 12, 7), 'Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting', 1.3395846311477841], [datetime.date(2020, 12, 5), 'Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting', 1.3395846311477841], [datetime.date(2020, 12, 4), 'Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19', 2.2724140918249276], [datetime.date(2020, 12, 2), 'Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19', -0.8673925409195257], [datetime.date(2020, 11, 24), 'Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference', 0.9395392643179388], [datetime.date(2020, 11, 20), \"Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19\", 0.37662251521238244], [datetime.date(2020, 11, 20), 'Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement', 0.37662251521238244], [datetime.date(2020, 11, 19), 'Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19', 3.6016239621666437], [datetime.date(2020, 11, 19), 'Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes', 3.6016239621666437], [datetime.date(2020, 11, 18), 'Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial', 1.052940398784301], [datetime.date(2020, 11, 12), 'Lilly to Participate in Wolfe Research Virtual Healthcare Conference', -0.386301257754524], [datetime.date(2020, 11, 12), 'Lilly to Participate in Bernstein Operational Decisions Conference', -0.386301257754524], [datetime.date(2020, 11, 11), 'Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program', -4.236432488985899], [datetime.date(2020, 11, 9), \"Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19\", 2.7429084371914207], [datetime.date(2020, 11, 5), 'Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting', -3.4608281630830553], [datetime.date(2020, 11, 5), 'Aarti Shah to Retire as Lilly Chief Information and Digital Officer', -3.4608281630830553], [datetime.date(2020, 11, 2), 'ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis', -1.1910101910440951], [datetime.date(2020, 10, 31), 'EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis', -1.1910101910440951], [datetime.date(2020, 10, 30), 'Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata', -0.0987761903529434], [datetime.date(2020, 10, 29), 'New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis', -1.180440383900482], [datetime.date(2020, 10, 28), \"Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine\", 1.576762641645986], [datetime.date(2020, 10, 28), 'Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19', 1.576762641645986], [datetime.date(2020, 10, 27), 'Lilly Reports Third-Quarter Financial Results, Updates Guidance', -1.3022542566823285], [datetime.date(2020, 10, 23), 'New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status', -0.3810992525862045], [datetime.date(2020, 10, 19), 'Lilly Declares Fourth-Quarter 2020 Dividend', -2.3748287132920374], [datetime.date(2020, 10, 15), 'Lilly Announces Agreement to Acquire Disarm Therapeutics', -0.2669142463667253], [datetime.date(2020, 10, 12), \"Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial\", -4.497594377955216], [datetime.date(2020, 10, 9), \"Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment\", 0.25890970895060506], [datetime.date(2020, 10, 8), 'Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement', 2.855685002735844], [datetime.date(2020, 10, 8), 'Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen', 2.855685002735844], [datetime.date(2020, 10, 8), 'Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity', 2.855685002735844], [datetime.date(2020, 10, 8), 'Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries', 2.855685002735844], [datetime.date(2020, 10, 7), 'Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs', 3.2442921076688744], [datetime.date(2020, 10, 7), 'Lilly and Dexcom team up on new program to help improve diabetes management', 3.2442921076688744], [datetime.date(2020, 10, 6), 'REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study', 1.3628170993610822], [datetime.date(2020, 9, 20), 'Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer', -2.208725914529043], [datetime.date(2020, 9, 18), \"CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis\", -0.5688639831000171], [datetime.date(2020, 9, 17), 'Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies', 2.6204682322316852], [datetime.date(2020, 9, 16), 'Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting', 0.49190942771270807], [datetime.date(2020, 9, 15), 'Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care', 0.6624409034855372], [datetime.date(2020, 9, 15), 'US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack', 0.6624409034855372], [datetime.date(2020, 9, 14), 'Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial', 0.6596420239253984], [datetime.date(2020, 9, 11), 'Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference', 0.9664517794877651], [datetime.date(2020, 9, 11), 'Lilly to Participate in Morgan Stanley Global Healthcare Conference', 0.9664517794877651], [datetime.date(2020, 9, 11), 'REYVOW® (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study', 0.9664517794877651], [datetime.date(2020, 9, 10), 'Lilly Announces Webcast to Discuss ESMO 2020 Presentations', -1.2087272088815704], [datetime.date(2020, 9, 10), 'Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes', -1.2087272088815704], [datetime.date(2020, 9, 10), 'Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020', -1.2087272088815704], [datetime.date(2020, 9, 9), 'Lilly Announces Leadership Changes', -3.0091589780918913], [datetime.date(2020, 9, 3), 'FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes', -0.8481884775986415], [datetime.date(2020, 8, 29), 'Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction', -0.033912562776910765], [datetime.date(2020, 8, 27), 'New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers', -2.1990036056009745], [datetime.date(2020, 8, 18), 'Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement', 0.09193361934058139], [datetime.date(2020, 8, 3), 'Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)', 1.3238650800802207], [datetime.date(2020, 7, 30), 'Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance', -5.42950254038429], [datetime.date(2020, 7, 30), 'Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes', -5.42950254038429], [datetime.date(2020, 7, 28), \"Lilly's P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA\", 0.04946406660548832], [datetime.date(2020, 7, 21), \"Data from Lilly at Alzheimer's Association International Conference 2020® (AAIC® 2020) to Showcase Clinical Advances in Alzheimer's Research\", -1.231507977747643], [datetime.date(2020, 7, 17), 'Lilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement', 0.5986296445794097], [datetime.date(2020, 7, 17), \"Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis\", 0.5986296445794097], [datetime.date(2020, 7, 15), 'Lilly Declares Third-Quarter 2020 Dividend', -0.1151559004805199], [datetime.date(2020, 6, 25), 'Central Indiana Racial Equity Fund Launches with more than $2.2 Million in Initial Commitments', 3.18736013116478], [datetime.date(2020, 6, 24), 'Lilly launches program about what people with diabetes should “Know Before the Low”', 2.646445926204135], [datetime.date(2020, 6, 19), 'Full results from EMPERIAL exercise ability trials presented', -1.1093851200226454], [datetime.date(2020, 6, 17), 'Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine', -1.9618862280395968], [datetime.date(2020, 6, 16), \"Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications\", 2.281689445457505], [datetime.date(2020, 6, 16), 'Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer', 2.281689445457505], [datetime.date(2020, 6, 15), 'Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients', 13.26126883114019], [datetime.date(2020, 6, 13), 'Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections', 13.26126883114019], [datetime.date(2020, 6, 13), 'Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice', 13.26126883114019], [datetime.date(2020, 6, 12), 'Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life', -2.8405909169811934], [datetime.date(2020, 6, 12), 'Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)', -2.8405909169811934], [datetime.date(2020, 6, 12), 'Lilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event', -2.8405909169811934], [datetime.date(2020, 6, 9), \"First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial\", 0.8278268410378314], [datetime.date(2020, 6, 8), 'Lilly to Participate in Goldman Sachs Global Healthcare Conference', 1.5959176894629248], [datetime.date(2020, 6, 8), 'Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment', 1.5959176894629248], [datetime.date(2020, 6, 3), 'EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus', -1.7450547218634784], [datetime.date(2020, 6, 3), \"EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis\", -1.7450547218634784], [datetime.date(2020, 6, 1), \"Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)\", -0.3964538893048079], [datetime.date(2020, 6, 1), \"Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans\", -0.3964538893048079], [datetime.date(2020, 5, 29), \"Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer\", 0.5182027995009415], [datetime.date(2020, 5, 28), \"Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease\", 3.609023516333578], [datetime.date(2020, 5, 26), 'Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model', -3.713116156068965], [datetime.date(2020, 5, 26), \"Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction\", -3.713116156068965], [datetime.date(2020, 5, 26), 'Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure', -3.713116156068965], [datetime.date(2020, 5, 19), \"Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease\", -2.429328843267474], [datetime.date(2020, 5, 13), 'Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020', 1.3169691604061882], [datetime.date(2020, 5, 8), 'Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers', 2.7436210181224148], [datetime.date(2020, 5, 8), 'Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes', 2.7436210181224148], [datetime.date(2020, 5, 5), 'Lilly to Participate in UBS Virtual Global Healthcare Conference', 1.8381212142304049], [datetime.date(2020, 5, 4), 'Lilly Declares Second-Quarter 2020 Dividend', 2.0520555834390737], [datetime.date(2020, 5, 4), 'Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19', 2.0520555834390737], [datetime.date(2020, 4, 30), 'Lilly to Participate in Bank of America Securities Health Care Conference', -1.021924421354492], [datetime.date(2020, 4, 23), 'Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance', 3.5291314825500852], [datetime.date(2020, 4, 16), 'Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available', 2.7973751615892746], [datetime.date(2020, 4, 10), 'Lilly Begins Clinical Testing of Therapies for COVID-19', 4.063261955752932], [datetime.date(2020, 4, 8), 'Lilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement', 2.525201939202506], [datetime.date(2020, 4, 7), 'Eli Lilly and Company to Hold 2020 Annual Meeting of Shareholders Virtually', 2.1132681214302487], [datetime.date(2020, 4, 7), 'New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.', 2.1132681214302487], [datetime.date(2020, 4, 1), 'Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic', 5.753282656218031], [datetime.date(2020, 4, 1), 'Governor Holcomb and Mayor Hogsett announce coalition to flatten the COVID-19 curve across state, public invited to make commitment', 5.753282656218031], [datetime.date(2020, 3, 31), 'Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines', -0.39583269810498656], [datetime.date(2020, 3, 30), \"Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis\", 3.4962479237270654], [datetime.date(2020, 3, 24), 'Updates from Lilly about insulin supply and affordability', -1.066076306751545], [datetime.date(2020, 3, 23), 'Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic', 1.5786466152385124], [datetime.date(2020, 3, 22), 'Lilly to Provide Drive-Through COVID-19 Testing for Indianapolis Health Care Workers', 1.5786466152385124], [datetime.date(2020, 3, 20), 'US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes', -11.012183713772798], [datetime.date(2020, 3, 20), 'Kathryn Beiser to join Lilly as Vice President, Global Communications', -11.012183713772798], [datetime.date(2020, 3, 18), 'Lilly, Indiana State Department of Health Partner to Accelerate COVID-19 Testing Using Lilly Research Laboratories', -2.441965410202334], [datetime.date(2020, 3, 16), 'Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata', 8.519549606031509], [datetime.date(2020, 3, 12), 'AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19', 6.156264934937568], [datetime.date(2020, 3, 12), 'US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease', 6.156264934937568], [datetime.date(2020, 3, 11), 'Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D', -10.66497875117332], [datetime.date(2020, 3, 9), 'Lilly to Participate in Barclays Global Healthcare Conference', 5.07825683094356], [datetime.date(2020, 3, 3), \"Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines\", 5.057719725802571], [datetime.date(2020, 3, 2), 'U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis', 1.9722085835568073], [datetime.date(2020, 2, 28), 'Eli Lilly and Company Statement on ICER Final Report for Acute Treatments for Migraine: Effectiveness and Value', 4.862983622282209], [datetime.date(2020, 2, 26), \"FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer\", -5.294544291065827], [datetime.date(2020, 2, 21), 'Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease', -2.3090831407116985], [datetime.date(2020, 2, 21), 'Lilly to Participate in Cowen Health Care Conference', -2.3090831407116985], [datetime.date(2020, 2, 21), 'Lilly To Participate in SVB Leerink Global Healthcare Conference', -2.3090831407116985], [datetime.date(2020, 2, 20), 'Lilly Completes Acquisition of Dermira', 0.2886335608440795], [datetime.date(2020, 2, 10), 'Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study', 1.9063935130757346], [datetime.date(2020, 2, 7), 'Lilly to Participate in Guggenheim Healthcare Talks Idea Forum', -1.1751704873670117], [datetime.date(2020, 1, 31), \"Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription\", -1.3120496130023558], [datetime.date(2020, 1, 31), \"CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes\", -1.3120496130023558], [datetime.date(2020, 1, 30), 'Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition', 1.0455320287949414], [datetime.date(2020, 1, 30), 'Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis', 1.0455320287949414], [datetime.date(2020, 1, 29), 'Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application', 2.214893043757827], [datetime.date(2020, 1, 28), 'Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities', 0.8791216182892294], [datetime.date(2020, 1, 27), 'US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes', 1.3786814819962343], [datetime.date(2020, 1, 27), 'Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine', 1.3786814819962343], [datetime.date(2020, 1, 24), 'Anat Hakim to join Lilly as General Counsel', -2.559458647794714], [datetime.date(2020, 1, 21), 'Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant', 1.455193798081765], [datetime.date(2020, 1, 16), 'Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement', -1.6119441262439589], [datetime.date(2020, 1, 15), \"Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease\", 0.6009713005216115], [datetime.date(2020, 1, 14), 'Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®', 1.5024046208379138]]\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "import yfinance as yf\n",
    "from datetime import datetime\n",
    "from datetime import timedelta\n",
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "data = []\n",
    "offset = 0\n",
    "\n",
    "ticker = 'lly'\n",
    "\n",
    "stock_hist = get_df(ticker)\n",
    "\n",
    "# create break\n",
    "while True:\n",
    "    \n",
    "    headers = {\"User-Agent\": \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/94.0.4606.81 Safari/537.36\"}\n",
    "    \n",
    "    s = requests.Session()\n",
    "    html = requests.get(f'https://lilly.mediaroom.com/index.php?s=9042&l=100&o={offset}/', headers=headers)\n",
    "    \n",
    "\n",
    "    content = BeautifulSoup(html.content) \n",
    "\n",
    "    articles = content.find_all('div',attrs={'class': 'wd_item_wrapper'})\n",
    "    \n",
    "        \n",
    "    if not content:\n",
    "        break\n",
    "\n",
    "    \n",
    "    for article in articles:\n",
    "        date = article.find('div', attrs={'wd_date'}).text.lstrip()\n",
    "        title = article.find('div', attrs={'wd_title'}).text\n",
    "        \n",
    "        \n",
    "        date = date.lstrip().rstrip()    # remove starting and trailing whitespaces\n",
    "        title = title.lstrip().rstrip() \n",
    "        \n",
    "        \n",
    "        \n",
    "        date = datetime.strptime(date, '%B %d, %Y').date()\n",
    "        pct_change = changes_from_press(stock_hist, date, 1)\n",
    "        \n",
    "        data.append([date, title, pct_change])\n",
    "    print(data)\n",
    "        \n",
    "\n",
    "    \n",
    "    offset = offset + 100\n",
    "\n",
    "\n",
    "data = pd.DataFrame(data, columns=['date', 'press title', '1d change'])\n",
    "\n",
    "data = data.dropna()\n",
    "\n",
    "dates_str = [date.strftime(\"%m/%d/%Y\") for date in data['date'].tolist()]\n",
    "result = data.to_json(orient=\"values\", index=True)\n",
    "\n",
    "\n",
    "dict_data = {\n",
    "    'ticker': ticker,\n",
    "    'data': json.loads(result),\n",
    "    },\n",
    "\n",
    "\n",
    "with open(f'./data/{ticker}.json', 'w', encoding='utf-8') as f:\n",
    "    json.dump(dict_data, f, ensure_ascii=False, indent=4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d8a81af2",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
